CA3084326A1 - Long-acting conjugates of glp-2 derivatives - Google Patents

Long-acting conjugates of glp-2 derivatives Download PDF

Info

Publication number
CA3084326A1
CA3084326A1 CA3084326A CA3084326A CA3084326A1 CA 3084326 A1 CA3084326 A1 CA 3084326A1 CA 3084326 A CA3084326 A CA 3084326A CA 3084326 A CA3084326 A CA 3084326A CA 3084326 A1 CA3084326 A1 CA 3084326A1
Authority
CA
Canada
Prior art keywords
glp
derivative
lysine
group
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3084326A
Other languages
English (en)
French (fr)
Inventor
Jaehyuk Choi
Min Young Kim
In Young Choi
Sung Youb Jung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hanmi Pharmaceutical Co Ltd
Original Assignee
Hanmi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharmaceutical Co Ltd filed Critical Hanmi Pharmaceutical Co Ltd
Publication of CA3084326A1 publication Critical patent/CA3084326A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3084326A 2017-09-28 2018-09-28 Long-acting conjugates of glp-2 derivatives Pending CA3084326A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20170126577 2017-09-28
KR10-2017-0126577 2017-09-28
PCT/KR2018/011586 WO2019066586A1 (ko) 2017-09-28 2018-09-28 글루카곤 유사 펩타이드-2(glp-2) 유도체의 지속형 결합체

Publications (1)

Publication Number Publication Date
CA3084326A1 true CA3084326A1 (en) 2019-04-04

Family

ID=65902619

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3084326A Pending CA3084326A1 (en) 2017-09-28 2018-09-28 Long-acting conjugates of glp-2 derivatives

Country Status (22)

Country Link
US (3) US11530249B2 (cg-RX-API-DMAC7.html)
EP (1) EP3689898B1 (cg-RX-API-DMAC7.html)
JP (2) JP7751381B2 (cg-RX-API-DMAC7.html)
KR (2) KR102681143B1 (cg-RX-API-DMAC7.html)
CN (1) CN111433221B (cg-RX-API-DMAC7.html)
AR (1) AR113258A1 (cg-RX-API-DMAC7.html)
AU (1) AU2018339210B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020006189A2 (cg-RX-API-DMAC7.html)
CA (1) CA3084326A1 (cg-RX-API-DMAC7.html)
DK (1) DK3689898T3 (cg-RX-API-DMAC7.html)
EA (1) EA202090571A1 (cg-RX-API-DMAC7.html)
ES (1) ES3075688T3 (cg-RX-API-DMAC7.html)
FI (1) FI3689898T3 (cg-RX-API-DMAC7.html)
IL (1) IL273528B2 (cg-RX-API-DMAC7.html)
MX (1) MX2020004453A (cg-RX-API-DMAC7.html)
PH (1) PH12020550105A1 (cg-RX-API-DMAC7.html)
PT (1) PT3689898T (cg-RX-API-DMAC7.html)
SA (1) SA520411644B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202002563WA (cg-RX-API-DMAC7.html)
TW (2) TWI794897B (cg-RX-API-DMAC7.html)
WO (1) WO2019066586A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202001888B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4154869A4 (en) * 2020-05-22 2025-01-22 Hanmi Pharm. Co., Ltd. Liquid formulation of long-acting conjugate of glp-2

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202111312UA (en) 2019-06-14 2021-12-30 Zealand Pharma As Pharmaceutical parenteral composition of dual glp1/2 agonist
EP4082561A4 (en) * 2019-12-24 2024-02-07 Hanmi Pharm. Co., Ltd. Pharmaceutical composition for preventing or treating metabolic bone diseases, comprising glp-2 or conjugate thereof
US20230110689A1 (en) 2020-03-30 2023-04-13 Zealand Pharma A/S Agonist combination
CN115697375A (zh) * 2020-04-03 2023-02-03 韩美药品株式会社 预防或治疗放疗、化疗或其组合引发的粘膜炎的包含glp-2衍生物或其长效缀合物的药物组合物
CA3182260A1 (en) 2020-06-09 2021-12-16 Gleb Feldman Manufacture, formulation and dosing of apraglutide
CA3201916A1 (en) * 2020-12-24 2022-06-30 Hanmi Pharm. Co., Ltd. Combination therapy of insulinotropic peptide and glp-2, for preventing or treating short bowel syndrome
US20250276044A1 (en) * 2022-04-18 2025-09-04 Hanmi Pharm. Co., Ltd. COMBINATION THERAPY COMPRISING GLP-2, AND INSULINOTROPIC PEPTIDE, TNFa INHIBITOR, OR BOTH FOR PREVENTING OR TREATING BOWEL DISEASE
JP2026501948A (ja) 2022-12-23 2026-01-19 ハンミ ファーマシューティカル カンパニー リミテッド Glp-2誘導体又はその持続型結合体を含む移植片対宿主病の予防又は治療用薬学的組成物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
DK1360202T3 (da) * 2001-02-16 2008-09-22 Conjuchem Biotechnologies Inc Langvarigt glucagon-lignende peptid 2 (GLP-2) til behandling af gastrointestinale sygdomme og lidelser
US20090238838A1 (en) * 2003-11-13 2009-09-24 Hanmi Pharm. Ind. Co. Ltd. Insulinotropic peptide conjugate using an immunoglobulin fc
ES2347902T3 (es) * 2004-04-23 2010-11-22 Conjuchem Biotechnologies Inc. Canadian Corporation 4528590 Fase solida para uso en un procedimiento para la purificacion de conjugados de albumina.
DE602006020123D1 (de) * 2005-05-04 2011-03-31 Zealand Pharma As Glucagon-like-peptide-2- (glp-2-) analoga
JP2008169195A (ja) * 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
US20110171164A1 (en) * 2008-09-19 2011-07-14 Nektar Therapeutics Polymer conjugates of glp-2-like peptides
KR101746686B1 (ko) * 2010-10-26 2017-06-15 한미사이언스 주식회사 면역글로불린 단편을 이용한 글루카곤 유사 펩타이드―2(glp―2)약물 결합체
ES2687651T3 (es) * 2011-09-12 2018-10-26 Amunix Operating Inc. Composiciones de péptido-2 similar a glucagón y métodos para producir y usar los mismos
KR101895047B1 (ko) * 2011-12-30 2018-09-06 한미사이언스 주식회사 면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4154869A4 (en) * 2020-05-22 2025-01-22 Hanmi Pharm. Co., Ltd. Liquid formulation of long-acting conjugate of glp-2

Also Published As

Publication number Publication date
US20230090790A1 (en) 2023-03-23
IL273528B2 (en) 2025-08-01
BR112020006189A2 (pt) 2020-10-13
US20200262888A1 (en) 2020-08-20
NZ762962A (en) 2024-07-05
ES3075688T3 (en) 2026-08-06
EP3689898A4 (en) 2021-06-16
AR113258A1 (es) 2020-03-11
CN111433221B (zh) 2024-12-27
EP3689898B1 (en) 2026-04-29
US20220251164A1 (en) 2022-08-11
TWI794897B (zh) 2023-03-01
PT3689898T (pt) 2026-07-16
FI3689898T3 (fi) 2026-07-21
KR102681144B1 (ko) 2024-07-04
KR20190037181A (ko) 2019-04-05
JP7751381B2 (ja) 2025-10-08
US12703730B2 (en) 2026-08-11
ZA202001888B (en) 2021-05-26
JP2020534840A (ja) 2020-12-03
AU2018339210B2 (en) 2023-02-02
SA520411644B1 (ar) 2024-02-25
TWI795443B (zh) 2023-03-11
IL273528B1 (en) 2025-04-01
TW202142560A (zh) 2021-11-16
EP3689898A1 (en) 2020-08-05
MX2020004453A (es) 2020-07-24
DK3689898T3 (da) 2026-07-27
KR102681143B1 (ko) 2024-07-04
KR20240013836A (ko) 2024-01-30
PH12020550105A1 (en) 2020-12-07
WO2019066586A1 (ko) 2019-04-04
US11530249B2 (en) 2022-12-20
AU2018339210A1 (en) 2020-04-16
TW201927806A (zh) 2019-07-16
CN111433221A (zh) 2020-07-17
JP2023138505A (ja) 2023-10-02
SG11202002563WA (en) 2020-04-29
IL273528A (en) 2020-05-31
EA202090571A1 (ru) 2020-07-30

Similar Documents

Publication Publication Date Title
US20230090790A1 (en) Long-acting conjugates of glp-2 derivatives
KR102179392B1 (ko) 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체의 지속형 결합체
TWI708782B (zh) 新穎胰島素類似物及其用途
US10253082B2 (en) Long-acting insulin and use thereof
CN119303105A (zh) 包括胰岛素和glp-1/胰高血糖素双重激动剂的用于治疗糖尿病的组合物
EP3689382A1 (en) Long-acting single-chain insulin analog and conjugate thereof
CN110536899B (zh) 对胰岛素受体具有降低的亲和力的胰岛素类似物复合物及其用途
KR20170080526A (ko) Fgf21 아날로그, fgf21 결합체, 및 이의 용도
HK40024582A (en) Long-acting conjugate of glucagon-like peptide-2 (glp-2) derivative
EA047924B1 (ru) Конъюгаты производных glp-2 пролонгированного действия
HK40025554B (en) Insulin analog conjugates and use thereof
HK40025554A (en) Insulin analog conjugates and use thereof
HK1235013A1 (en) Composition for treating diabetes mellitus comprising insulin and a glp-1/ glucagon dual agonist

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230926

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240826

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240826

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240826

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20241024

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250224

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250225

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250707

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250707

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250714

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250714

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20251201

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20260401

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260402

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260402

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260402

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260713

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260713